

Sengenics, a Portfolio Company of Summa Equity, Acquired by Standard BioTools



Acquired by



38th

Cross-border
Transaction

68th

Diagnostic &
Tools Deal

53rd

International
Transaction

Sengenics, a Portfolio Company of Summa Equity, Acquired by Standard BioTools to Strengthen its Proteomics Portfolio for Biopharma and Translational Research.

The proteomics market is poised for substantial growth, projected to increase from \$31.6 billion in 2024 to \$94.7 billion by 2035. Proteomics, the large-scale study of proteins in cells and tissues, offers critical insights into cellular functions and disease pathways, playing a vital role in advancing personalized medicine, cancer immunotherapy, and treatments for autoimmune diseases. As pharmaceutical and biotech companies increasingly prioritize complex biological mechanisms for drug discovery and development, the demand for sophisticated proteomic tools and technology continues to rise.

Sengenics is a functional proteomics company enabling the detection of autoantibody biomarkers and protein interactions. Founded in 2008, the innovative immunoproteomics company leverages its KREX™ protein-folding technology to enable precise antibody profiling. The core technology is utilized across a variety of offerings, including the flagship

i-OME™ Discovery platform which boasts a library of 1800+ curated disease relevant auto-antibody targets.

Recognizing the strategic value of Sengenics' cutting-edge Krex protein folding technology, Standard BioTools saw a compelling opportunity to integrate KREX™ precision antibody profiling services and kits to its SomaScan™ suite of solutions. The expanded offering fits squarely into Standard BioTool's "omics as a service offering", strengthening its portfolio, particularly in biopharma and translation research.

Led by members of Crosstree's Investment Banking and Strategic Advisory & Originations team, Crosstree delivered an unique, integrated solution to assist Summa Equity in evaluating a range of strategic alternatives for Sengenics and advising on the transaction with Standard BioTools. This integrated approach enabled a holistic and efficient strategic alternatives review for Sengenics, ultimately leading to the successful transaction with StandardBio Tools.

"Crosstree's proven track record of superior outcomes is the result of balanced, hands-on guidance from start to close. Partner with the leading health science experts today."



GREG BARE

Director

gregory.bare@crosstreecapital.com

813-774-4754

Crosstree's experts are specialists in the nuances of the health sciences, prioritizing corporate core values and providing:

- Deep analytics of capabilities and gaps
- Systemized tactical strategies and a road map to success
- Engaged experts in market analysis, financials, and premium valuations
- Targeted and qualified prospects
- Up-to-date industry trend analysis and forecasting

Meeting the needs of both the buyer and the seller by the numbers and beyond is Crosstree's specialty.



About Sengenics

Sengenics is a Functional Proteomics company that leverages its patented KREX™ technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX™ can also be used to identify autoantibody biomarkers that may be used to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

About Standard BioTools

Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy.



Other Recent Health Sciences Transactions:

Project Gateway
(Pending)

Specialty Pharmacy Supply-Chain & Infusion Practice Management Software

oanju

Acquired by

VALSOFT

CALYX™

Divested its "Enterprise Technology" Division to

eNNOV
Software for Life

physIQ

Acquired by

prolao

PINNACLE
CLINICAL RESEARCH
A portfolio company of

LVC
LONGUEVILLE CAPITAL
Acquired

KERWIN MEDICAL
CENTER

BBi Solutions

A Portfolio Company of

NOVO
holdings

Acquired

IBEX